Dampness and moulds in workplace buildings: Associations with incidence and remission of sick building syndrome (SBS) and biomarkers of inflammation in a 10 year follow-up study
Abstract
There are few longitudinal studies on health effects of dampness and moulds in workplace buildings. We studied associations between dampness and indoor moulds in workplace buildings and selected biomarkers as well as incidence and remission of sick building syndrome (SBS). The study was based on a ten-year prospective study (1992-2002) in a random sample of adults (N=429) from the Uppsala part of the European Community Respiratory Health Survey (ECRHS). The 10-year incidence (onset) of general, mucosal, dermal symptoms and any symptom improved when away from the workplace (work-related symptoms) was 7.2%, 11.6%, 6.4% and 9.4% respectively. The 10-year remission of general, mucosal, dermal symptoms and work-related symptoms was 71.4%, 57.1%, 70.4% and 72.2% respectively. Signs of dampness in the floor construction in any workplace building during follow up (cumulative exposure) was associated with incidence of mucosal symptoms (OR=2.43). Cumulative exposure to moldy odor was associated with incidence of work-related symptoms (OR=2.69). Cumulative exposure to dampness or moulds was associated with decreased remission of work-related symptoms (OR=0.20 for water leakage, OR=0.17 for floor dampness, and OR=0.17 for visible indoor mould growth). Working in a building repaired because of dampness (repaired building) or mould was associated with decreased remission of work-related symptoms (OR=0.32). Any dampness or moulds at baseline in the workplace building was associated with increased bronchial responsiveness (BR) and higher levels of Eosinphilic Cationic Protein (ECP) in serum and Eosinophilic counts in blood at baseline. Cumulative exposure to dampness and moulds, and work in a repaired building, was associated with increased BR at follow-up. In general, dampness and moulds in the workplace building is associated with increased incidence and decreased remission of SBS, as well as increased bronchial responsiveness and eosinophilic inflammation.
Symptom Clusters
Cited By (15)
- Indoor microbiome and allergic diseases: From theoretical advances to prevention strategiesEco-Environment & Health · 2022
- NIOSH Dampness and Mold Assessment Tool (DMAT): Documentation and Data Analysis of Dampness and Mold-Related Damage in Buildings and Its ApplicationBuildings · 2022
- Medizinisch klinische Diagnostik bei Schimmelpilzexposition in Innenräumen – Update 2023 (AWMF-Register-Nr. 161/001)Pneumologie · 2024
- The Continuum of Severity of Functional Impairment Due to Indoor Air SymptomsJournal of Occupational and Environmental Medicine · 2023
- In Vitro Systems for Toxicity Evaluation of Microbial Volatile Organic Compounds on Humans: Current Status and TrendsJournal of Fungi · 2022
- What effect do mycotoxins, cell wall components, enzymes and other mold components and metabolites have on our health?Allergo Journal International · 2024
Related Papers
- Poorly controlled asthma – Easy wins and future prospects for addressing fungal allergyAllergology International · 2023 · 5 shared tags
- The Sick Building Syndrome as a Part of the Autoimmune (Autoinflammatory) Syndrome Induced by Adjuvant2024 · 5 shared tags
- Medizinisch klinische Diagnostik bei Schimmelpilzexposition in Innenräumen – Update 2023 (AWMF-Register-Nr. 161/001)Pneumologie · 2024 · 5 shared tags
- Onset of mucosal, dermal, and general symptoms in relation to biomarkers and exposures in the dwelling: a cohort study from 1992 to 2002Indoor Air · 2012 · 5 shared tags
- Clinical experience and results of a sentinel health investigation related to indoor fungal exposureEnvironmental Health Perspectives · 1999 · 5 shared tags
- Adverse human health effects associated with molds in the indoor environmentJournal of Occupational and Environmental Medicine · 2003 · 5 shared tags